
US and China Pre-Treatment Kit for Molecular Diagnosis of Sepsis Market Research Report Forecast to 2030
Description
US and China Pre-Treatment Kit for Molecular Diagnosis of Sepsis Market Research Report Forecast to 2030
The growth of the pre-treatment kit for molecular diagnosis of sepsis market is attributed to the Rising incidence of sepsis, advancements in molecular diagnostic technologies, and increasing investment in research and development and increasing geriatric population. However, limited awareness and education is anticipated to hamper market growth.
A pre-treatment kit refers to a collection of components, reagents, and materials used in the initial steps of a diagnostic or analytical process. It is specifically designed to prepare a sample for further analysis or testing. In the context of molecular diagnosis of sepsis, a pre-treatment kit would include items necessary for the collection, preservation, and processing of patient samples to facilitate the accurate and efficient detection of sepsis-causing pathogens or related markers through molecular diagnostic techniques such as PCR or nucleic acid amplification.
The expected growth in the market can be attributed to the growing prevalence of sepsis and increasing geriatric population. However, the market is also held back by a lack of skilled personnel. Nevertheless, it is anticipated that the growing public-private funding for sepsis diagnostic research activities will create lucrative opportunities for the players operating in the US & China pre-treatment kit for molecular diagnosis of sepsis market.
Market Segmentation
Based on product, the US & China pre-treatment kits for molecular diagnosis of sepsis market have been segmented into automated extraction equipment and multi-well chamber construction kits. The multi-well chamber construction kits segment dominated the market in 2022, while the automated extraction equipment segment is projected to be the fastest-growing during the forecast period, 2023–2030.
Regional Analysis
The rising incidence of sepsis, the increasing burden of hospital-acquired infections, a growing number of pneumonia cases, the increase in the number of sepsis procedures, and an increase in funding for sepsis-related research activities are the major factors driving the growth of the US pre-treatment kits for molecular diagnosis of sepsis market.
In China, sepsis is a leading cause of illness and mortality. Sepsis is common in this country due to its vast population and diverse healthcare system. The illness causes a significant strain on healthcare systems, resulting in more hospital admissions, longer hospital stays, and higher healthcare expenses. Additionally, however, in China, various obstacles impede appropriate sepsis care. Limited awareness of sepsis symptoms and early warning signals among healthcare personnel and the public contributes to delayed diagnosis. Furthermore, the lack of standardized methods for sepsis management, as well as variable adherence to existing standards, provide substantial challenges.
Major Players
The key market players are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc (US), Abbott (US), Siemens Medical Solutions USA, Inc (Germany), and Qiagen (Germany). Other key players contributing to the market growth include T2 Biosystems, Inc (US), Luminex Corporation (US), Bioneer Corporation (South Korea), Cepheid (US), and BioMérieux SA (France).
Companies Mentioned
F. Hoffmann-La Roche Ltd (Switzerland)
Thermo Fisher Scientific Inc (US)
Abbott (US)
Siemens Medical Solutions USA
Inc (Germany)
and Qiagen (Germany). Other key players contributing to the market growth include T2 Biosystems
Inc (US)
Luminex Corporation (US)
Bioneer Corporation (South Korea)
Cepheid (US)
and BioMérieux SA (France).
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Table of Contents
70 Pages
- 1 Executive Summary 11
- 1.1 Overview 11
- 2 Market Introduction 12
- 2.1 Definition 12
- 2.2 Scope Of The Study 12
- 2.3 Research Objective 12
- 2.4 Market Structure 13
- 2.5 Assumptions & Limitations 13
- 3 Research Methodology 14
- 3.1 Data Mining 14
- 3.2 Secondary Research 15
- 3.3 Primary Research 16
- 3.4 Breakdown Of Primary Respondents 17
- 3.5 Forecasting Techniques 18
- 3.6 Research Methodology For Market Size Estimation 19
- 3.6.1 Bottom-up Approach 20
- 3.6.2 Top-down Approach 20
- 3.7 Data Triangulation 21
- 3.8 Validation 21
- 4 Market Dynamics 22
- 4.1 Overview 22
- 4.2 Drivers 23
- 4.2.1 Growing Prevalence Of Sepsis 23
- 4.2.2 Increasing Geriatric Population 23
- 4.3 Restraints 24
- 4.3.1 Lack Of Skilled Personnel 24
- 4.3.2 Limited Awareness And Education 25
- 4.4 Opportunities 26
- 4.4.1 Growing Public-private Funding For Sepsis Diagnostic Reasearch Activities 26
- 5 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Product 27
- 5.1 Overview 27
- 5.2 Automated Extraction Equipment 29
- 5.3 Multi-well Chamber Construction Kits 29
- 6 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Country 30
- 6.1 Overview 30
- 6.1.1 Us 32
- 6.1.2 China 34
- 7 Competitive Landscape 35
- 7.1 Overview 35
- 7.2 Competitive Benchmarking 36
- 7.3 Major Growth Strategy In The Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market 37
- 7.4 The Leading Player In Terms Of The Number Of Developments In The Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market 37
- 7.5 Key Development Analysis 38
- 7.6 Key Developments & Growth Strategies 38
- 7.6.1 Product Launch/Product Approval 38
- 7.6.2 Merger/Acquisition 38
- 7.6.3 Expansion/ Investment 39
- 7.7 Major Players Sales Analysis 39
- 7.7.1 Sales 39
- 7.8 Major Players R&D Analysis 40
- 8 Company Profiles 41
- 8.1 Thermo Fisher Scientific Inc. 41
- 8.1.1 Company Overview 41
- 8.1.2 Financial Analysis 42
- 8.1.3 Products Offered 43
- 8.1.4 Key Developments 43
- 8.1.5 Swot Analysis 44
- 8.1.6 Key Strategies 44
- 8.2 F. Hoffmann-la Roche Ltd 45
- 8.2.1 Company Overview 45
- 8.2.2 Financial Overview 45
- 8.2.3 Products Offered 46
- 8.2.4 Key Developments 46
- 8.2.5 Swot Analysis 46
- 8.2.6 Key Strategies 47
- 8.3 Cepheid 48
- 8.3.1 Company Overview 48
- 8.3.2 Financial Overview 48
- 8.3.3 Product/Service Offered 48
- 8.3.4 Key Developments 48
- 8.3.5 Key Strategies 48
- 8.4 Biomérieux Sa 49
- 8.4.1 Company Overview 49
- 8.4.2 Financial Overview 50
- 8.4.3 Products Offered 51
- 8.4.4 Key Developments 51
- 8.4.5 Swot Analysis 52
- 8.4.6 Key Strategies 52
- 8.5 Siemens Medical Solutions Usa, Inc. 53
- 8.5.1 Company Overview 53
- 8.5.2 Financial Overview 54
- 8.5.3 Products Offered 54
- 8.5.4 Key Developments 54
- 8.5.5 Key Strategies 55
- 8.6 Abbott 56
- 8.6.1 Company Overview 56
- 8.6.2 Financial Overview 57
- 8.6.3 Products Offered 57
- 8.6.4 Key Developments 58
- 8.6.5 Swot Analysis 58
- 8.6.6 Key Strategies 58
- 8.7 T2 Biosystems, Inc 59
- 8.7.1 Company Overview 59
- 8.7.2 Financial Overview 60
- 8.7.3 Products Offered 60
- 8.7.4 Key Developments 61
- 8.7.5 Key Strategies 61
- 8.8 Luminex Corporation 62
- 8.8.1 Company Overviews 62
- 8.8.2 Financial Overview 62
- 8.8.3 Products Offered 62
- 8.8.4 Key Developments 62
- 8.8.5 Key Strategies 62
- 8.9 Bioneer Corporation 63
- 8.9.1 Company Overview 63
- 8.9.2 Financial Overview 63
- 8.9.3 Products Offered 64
- 8.9.4 Key Developments 64
- 8.9.5 Key Strategies 64
- 8.10 Qiagen 65
- 8.10.1 Company Overview 65
- 8.10.2 Financial Overview 66
- 8.10.3 Products Offered 66
- 8.10.4 Key Developments 67
- 8.10.5 Swot Analysis 67
- 8.10.6 Key Strategies 67
- 9 Appendix 68
- 9.1 References 68
- 9.2 Related Reports 69
- List Of Tables
- Table 1 List Of Assumptions & Limitations 13
- Table 2 Primary Interviews And Information Gathering Process 16
- Table 3 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Product,
- 2019–2030 (Usd Million) 28
- Table 4 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, For Automated
- Extraction Equipment, By Region, 2019–2030 (Usd Million) 29
- Table 5 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, For Multi-well
- Chamber Construction Kits, By Region, 2019–2030 (Usd Million) 29
- Table 6 Us And China: Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Region, 2019–2030 (Usd Million) 30
- Table 7 Us: Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Product, 2019–2030 (Usd Million) 33
- Table 8 China: Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Product, 2019–2030 (Usd Million) 34
- Table 9 Major Players In The Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market 35
- Table 10 Most Active Player In The Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market 37
- Table 11 Product Launch/Product Approval 38
- Table 12 Merger/Acquisition 38
- Table 13 Expansion/ Investment 39
- Table 14 Thermo Fisher Scientific Inc.: Products Offered 43
- Table 15 Thermo Fisher Scientific Inc.: Key Developments 43
- Table 16 F. Hoffmann-la Roche Ltd: Products Offered 46
- Table 17 Cepheid: Product/Service Offered 48
- Table 18 Biomérieux Sa: Products Offered 51
- Table 19 Siemens Medical Solutions Usa, Inc.: Products Offered 54
- Table 20 Abbott: Products Offered 57
- Table 21 Abbott: Key Developments 58
- Table 22 T2 Biosystems, Inc: Products Offered 60
- Table 23 T2 Biosystems, Inc: Key Developments 61
- Table 24 Luminex Corporation: Products Offered 62
- Table 25 Bioneer Corporation: Products Offered 64
- Table 26 Qiagen: Products Offered 66
- List Of Figures
- Figure 1 Market Synopsis 11
- Figure 2 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market 13
- Figure 3 Bottom-up And Top-down Approaches 19
- Figure 4 Market Dynamics: Analysis Of The Us & China Pre-treatment Kit For Molecular Diagnosis Of Sepsis 22
- Figure 5 Drivers Impact Analysis 24
- Figure 6 Restraint Impact Analysis 25
- Figure 7 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, Product Segment
- Attractiveness, 2019-2030 (Usd Million) 27
- Figure 8 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Product,
- 2022 & 2030 (Usd Million) 28
- Figure 9 Us And China: Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, By Country,
- 2022 & 2030 (Usd Million) 30
- Figure 10 Us And China: Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market Share (%), By Region, 2022 31
- Figure 11 Us Market Analysis: Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, 2019-2030 (Usd Million) 32
- Figure 12 China Market Analysis: Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market, 2019-2030 (Usd Million) 34
- Figure 13 Benchmarking Of Major Competitors 36
- Figure 14 Major Strategy Adopted By Key Players In The Us And China Pre-treatment Kit For Molecular
- Diagnosis Of Sepsis Market 37
- Figure 15 Us And China Pre-treatment Kit For Molecular Diagnosis Of Sepsis Market: Competitive Landscape 38
- Figure 16 Major Players Sales, 2022 39
- Figure 17 Major Player R&D Expenditure, 2022 40
- Figure 18 Thermo Fisher Scientific Inc.: Financial Overview Snapshot 42
- Figure 19 Thermo Fisher Scientific Inc.: Swot Analysis 44
- Figure 20 F. Hoffman La Roche Ltd: Financial Overview Snapshot 45
- Figure 21 F. Hoffman La Roche Ltd: Swot Analysis 46
- Figure 22 Biomérieux Sa: Financial Overview Snapshot 50
- Figure 23 Biomérieux Sa: Swot Analysis 52
- Figure 24 Siemens Medical Solutions Usa, Inc.: Financial Overview Snapshot 54
- Figure 25 Abbott: Financial Overview Snapshot 57
- Figure 26 Abbott: Swot Analysis 58
- Figure 27 T2 Biosystems, Inc: Financial Overview Snapshot 60
- Figure 28 Bioneer Corporation: Financial Overview Snapshot 63
- Figure 29 Qiagen: Financial Overview Snapshot 66
- Figure 30 Qiagen: Swot Analysis 67
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.